Trial Profile
Handai Candesartan anti-atherogenesis Trial on diabetic patients with hypertension using CT examination
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2012
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Cardiovascular disorders; Essential hypertension
- Focus Therapeutic Use
- 23 Sep 2011 New trial record
- 01 Apr 2010 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.